Protagonist Therapeutics, Inc.
General ticker "PTGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.3B (TTM average)
Protagonist Therapeutics, Inc. follows the US Stock Market performance with the rate: 45.7%.
Estimated limits based on current volatility of 2.4%: low 92.83$, high 97.39$
Factors to consider:
- Total employees count: 126 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Lack of approved products, Geopolitical risks, Economic downturns and volatility, Regulatory and compliance, Strategic risks and growth management
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [63.71$, 112.64$]
- 2026-12-31 to 2027-12-31 estimated range: [54.75$, 99.90$]
Financial Metrics affecting the PTGX estimates:
- Negative: with PPE of -42.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -4.43 < Investing cash flow per share per price, % of -0.88
- Positive: Shareholder equity ratio, % of 92.00 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PTGX quotes
Long-term PTGX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $60.00MM | $434.43MM | $46.02MM |
| Operating Expenses | $153.65MM | $181.59MM | $204.14MM |
| Operating Income | $-93.65MM | $252.84MM | $-158.13MM |
| Non-Operating Income | $14.70MM | $26.57MM | $28.82MM |
| R&D Expense | $120.16MM | $138.13MM | $159.29MM |
| Income(Loss) | $-78.95MM | $279.41MM | $-129.31MM |
| Taxes | $0.00MM | $4.22MM | $0.84MM |
| Profit(Loss)* | $-78.95MM | $275.19MM | $-260.30MM |
| Stockholders Equity | $336.68MM | $675.29MM | $614.71MM |
| Assets | $357.95MM | $744.73MM | $669.89MM |
| Operating Cash Flow | $-70.24MM | $184.15MM | $57.67MM |
| Capital expenditure | $0.61MM | $1.35MM | $1.59MM |
| Investing Cash Flow | $-39.26MM | $-299.48MM | $-49.33MM |
| Financing Cash Flow | $170.48MM | $25.85MM | $22.86MM |
| Earnings Per Share** | $-1.39 | $4.47 | $-4.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.